ZNF346 Knockout cell line (LN-229)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ZNF346 (zinc finger protein 346) encodes a nucleolar zinc finger protein that preferentially binds double-stranded RNA and RNA/DNA hybrids. Its zinc finger domains contribute to RNA binding and nucleolar localization, supporting a role in RNA-associated cellular processes. ZNF346 may also influence cell growth and survival and has been reported to protect neurons from inappropriate cell-cycle re-entry by promoting expression of the cell-cycle inhibitor p21.

Established in 1979, LN-229 is a widely recognized and standard human glioblastoma cell line. The line was isolated from cells taken from a patient presenting with a malignant right frontal parieto-occipital glioblastoma (PubMed: 10416987). LN-229 cells adhere stably in culture, displaying an epithelial-like morphology, and are extensively utilized to study apoptotic pathways, cellular autophagy, and tumor suppressor gene interactions within neuro-oncology. Consequently, LN-229 serves as a premier and robust in vitro platform utilized globally for investigating glioblastoma multiforme (GBM) progression mechanisms, blood-brain barrier penetrating candidate drug screenings, and the evaluation of targeted therapeutic modalities.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.